Stock Guru Profile News BlogsOn the heels of the news of Gross Profit INCREASES RXEI has unveiled their plan of physical growth.
December 12, 2007, is the date of the groundbreaking ceremony at the worksite of their new corporate facility in Nampa, Idaho which will be the site of a 17-acre campus over time.
RxElite will use the new facility to house corporate offices and consolidate warehousing space as well as position themselves for future growth as a part of their strategy to work with hard to manufacture generic pharmaceuticals.
RxElite expects to add over 150 core jobs.
The initial building will occupy 6 of the 17-acre site and will house an 83,000 square foot building designed to accommodate corporate offices, warehousing and distribution. Near and long-term plans allow for the organic growth of the facility at the new Nampa location, expanding operations that ultimately could encompass the full 17-acre site and create a fully integrated strategy around hard to manufacture generic pharmaceuticals.
Gross profit increased by $47,398 from $83,118 for the three months ended September 30, 2006 to $130,516 for the three months ended September 30, 2007.
Similarly, gross profit increased by $29,712 from $283,778 for the nine months ended September 30, 2006 to $313,490 for the nine months ended September 30, 2007.
Gross profit as a percentage of sales increased for both the three months and nine months ended September 30, 2007 resulting from a transition in product mix.
Management states: gross profit should improve and exceed historical levels in 2008, given the approval by the FDA and subsequent launch of generic Sevoflurane in May 2007.
RXEI EXPECTS to launch new products in 2008 and beyond and believe that such new products should achieve greater profitability as a result of barriers to entry, such as process patents or limited manufacturing capacity that may provide the prospect of a limited competitive field.
What we know:
Sevoflurane is the most widely used, inhalable anesthetic gas in the world.
RxElite is on track in sales.
Sales continue to DOUBLE MONTH to MONTH.
The price of Sevoflurane has not suffered significant erosion as it becomes generic.
SOUT is on target with their distribution of Sevoflurane in capturing the projected 11 to 15 percent of the market in the U.S.
Oppenheimer’s October report focuses on the manufacturer of Sevoflurane by Minrad.
RXEI is the exclusive U.S. distributor of Sevoflurane for Minrad.
Listen to Interview of CEO, Johnathan Houssian, for details!
RXEI: Oppenheimer’s October
RXEI Interview with CEO MP3:
RXEI Interview with CEO Windows Media:
http://www.stockguru.com/audio/sout10022007.wma
RxElite has agreements with over ninety percent of the U.S. market for generic drugs. These agreements represent 50 of the top 75 generic drug buyers. See Profile.
Power Point for Investor Profile from Rx Elite
Source: RxElite Holdings, Inc.
RxElite Holdings, Inc.
Ph: (208) 288-5550
Toll Free: (800) 414-1901
Fax: (208) 288-1191 Investor Relations
Charlie Forshee, 215-885-4981
investorrelations@rxelite.com
About RxElite Holdings, Inc.: RxElite Holdings, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.
Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause the our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
Disclosure: Pentony Enterprises LLC was compensated $18,000.00. Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC,9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com.
